Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease
NCT ID: NCT02991235
Last Updated: 2018-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2016-12-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
NCT03462121
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
NCT06402838
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
NCT01689233
Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease
NCT02389413
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PRJ212
PRJ212 is a nutritional product with active food ingredients.
PRJ212
6 capsules of study product will be taken daily and orally.
Placebo
Placebo is like PRJ212 without active food ingredients.
Placebo
6 capsules of study product will be taken daily and orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PRJ212
6 capsules of study product will be taken daily and orally.
Placebo
6 capsules of study product will be taken daily and orally.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a diagnosis of probable or possible Alzheimer's disease according to the NINCDS-ADRDA.
* Patients with mild Alzheimer's disease according to MMSE.
* Patients with ability to ingest oral medication.
* Patients able to undergo a MRI.
Exclusion Criteria
* Patients and caregivers unwilling or unable to perform cognitive testing.
* Patients taking part in an interventional clinical trial.
* Patients who have a risk of non-compliance to the study procedures.
* Patients with clinical or significant laboratory abnormalities.
* Patients treated with concomitant treatment or food supplements which could interfere with evaluation criteria.
60 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bioiberica
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martinez
Role: STUDY_DIRECTOR
Bioiberica, S.A.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundació ACE
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIO-PRJ-2015-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.